{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:54:53Z","timestamp":1792457693783,"version":"4.5.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recent studies have shown that local injection of secukinumab can achieve positive therapeutic effects when applied in the treatment of nail psoriasis. At present, there have been no other studies on the use of biological agents in the treatment of pediatric nail psoriasis. Three children were included in the study to evaluate the efficacy and safety of periungual injection and long-term injection of secukinumab in the treatment of nail psoriasis in children. It was found that local injection did not achieve a remarkable therapeutic effect. The nail lesions were improved continuously by subcutaneous injection once a month.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1435141","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:17:48Z","timestamp":1728404268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Intralesional secukinumab injection for pediatric nail psoriasis: does it have to be a positive outcome?"],"prefix":"10.3389","volume":"15","author":[{"given":"Xuesong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201471","article-title":"Nail psoriasis: diagnosis, assessment, treatment options, and unmet clinical needs","volume":"48","author":"Kaeley","year":"2021","journal-title":"J Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13402","article-title":"Clinical features and nail clippings in 52 children with psoriasis","volume":"35","author":"Uber","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ced.14314","article-title":"Management of nail psoriasis","volume":"46","author":"Thomas","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_124_20","article-title":"Intramatricial low-dose secukinumab injection for nail psoriasis","volume":"87","author":"He","year":"2021","journal-title":"Indian J dermatology venereology leprology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14933","article-title":"Intramatricial injection of anti-interleukin-17A antibody for six patients with nail psoriasis","volume":"47","author":"He","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3098","article-title":"Nail psoriasis: an updated review and expert opinion on available treatments, including biologics","volume":"99","author":"Bardazzi","year":"2019","journal-title":"Acta dermato-venereologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000323004","article-title":"Nail psoriasis successfully treated with intralesional methotrexate: case report","volume":"222","author":"Sar\u0131caoglu","year":"2011","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2022.2101999","article-title":"Pediatric chronic spontaneous urticaria: a brief clinician's guide","volume":"18","author":"Votto","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: A review in moderate to severe pediatric plaque psoriasis","volume":"23","author":"Blair","year":"2021","journal-title":"Paediatric Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1435141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:17:52Z","timestamp":1728404272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1435141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2024.1435141"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1435141","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"article-number":"1435141"}}